Axitinib
HER-2 Protein Overexpression
Lynkcell EuropeSmall moleculePhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the HER-2 Protein Overexpression cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TRASTUZUMAB NKGen Biotech, Inc. | Phase 2 | BB |
Zanidatamab Jazz Pharmaceuticals | Phase 2 | B |
Irinotecan Jin-Hee Ahn | Phase 2 | CCC |
Pyrotinib Tianjin Medical University Second Hospital | Phase 2 | CCC |
her2 dc1 vaccine H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | CCC |
View all 18 →
Same molecule, other indications
Axitinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →